Crossmark

Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa

Crossref DOI link: https://doi.org/10.1016/j.ad.2025.104582

Published Print: 2026-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Martorell, A.

Molina-Leyva, A.

Jiménez Morales, A.

Blanch, C. https://orcid.org/0000-0002-9792-0115
Funding

Funding for this research was provided by:

Novartis Farmaceutica SA
License Information

Text and Data Mining valid from 2026-05-01

Text and Data Mining valid from 2026-05-01

Version of Record valid from 2025-12-18
More Information

This article is maintained by: Elsevier

Article Title: Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2025.104582

Content Type: article

Copyright: © 2025 AEDV. Published by Elsevier España, S.L.U.